Gilead Sciences, Inc. (GILD) stock
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 12/30104% above fair value
$168.98−1.28 (-0.75%)
Close on Nov 18, 2026Market cap $209.59BP/E –Yield 1.87%
Gilead Sciences revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Gilead Sciences's revenue for the twelve months ending Sep 30, 2026 was $30.99B, up 6.5% year over year. For fiscal 2025 it was $29.44B, up 2.4% from the year before. Over ten years it grew -1.0% a year on average. The highest annual figure on record is $32.64B in fiscal 2015.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $29.44B | +2.4% |
| FY2024 | Dec 31, 2024 | $28.75B | +6.0% |
| FY2023 | Dec 31, 2023 | $27.12B | -0.6% |
| FY2022 | Dec 31, 2022 | $27.28B | -0.1% |
| FY2021 | Dec 31, 2021 | $27.31B | +10.6% |
| FY2020 | Dec 31, 2020 | $24.69B | +10.0% |
| FY2019 | Dec 31, 2019 | $22.45B | +1.5% |
| FY2018 | Dec 31, 2018 | $22.13B | -15.2% |
| FY2017 | Dec 31, 2017 | $26.11B | -14.1% |
| FY2016 | Dec 31, 2016 | $30.39B | -6.9% |
| FY2015 | Dec 31, 2015 | $32.64B | +31.1% |
| FY2014 | Dec 31, 2014 | $24.89B | +122.2% |
| FY2013 | Dec 31, 2013 | $11.20B | +15.5% |
| FY2012 | Dec 31, 2012 | $9.70B | +15.7% |
| FY2011 | Dec 31, 2011 | $8.39B | +5.5% |
| FY2010 | Dec 31, 2010 | $7.95B | +13.4% |
| FY2009 | Dec 31, 2009 | $7.01B | +31.4% |
| FY2008 | Dec 31, 2008 | $5.34B | +26.1% |
| FY2007 | Dec 31, 2007 | $4.23B | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $8.30B | +6.8% |
| Q2 FY2026 | Jun 30, 2026 | $7.80B | +10.2% |
| Q1 FY2026 | Mar 31, 2026 | $6.96B | +4.4% |
| Q4 FY2025 | Dec 31, 2025 | $7.93B | +4.7% |
| Q3 FY2025 | Sep 30, 2025 | $7.77B | +3.0% |
| Q2 FY2025 | Jun 30, 2025 | $7.08B | +1.8% |
| Q1 FY2025 | Mar 31, 2025 | $6.67B | -0.3% |
| Q4 FY2024 | Dec 31, 2024 | $7.57B | +6.4% |
| Q3 FY2024 | Sep 30, 2024 | $7.55B | +7.0% |
| Q2 FY2024 | Jun 30, 2024 | $6.95B | +5.4% |
| Q1 FY2024 | Mar 31, 2024 | $6.69B | +5.3% |
| Q4 FY2023 | Dec 31, 2023 | $7.11B | -3.7% |
| Q3 FY2023 | Sep 30, 2023 | $7.05B | +0.1% |
| Q2 FY2023 | Jun 30, 2023 | $6.60B | +5.4% |
| Q1 FY2023 | Mar 31, 2023 | $6.35B | -3.6% |
| Q4 FY2022 | Dec 31, 2022 | $7.39B | +2.0% |
| Q3 FY2022 | Sep 30, 2022 | $7.04B | -5.1% |
| Q2 FY2022 | Jun 30, 2022 | $6.26B | +0.7% |
| Q1 FY2022 | Mar 31, 2022 | $6.59B | +2.6% |
| Q4 FY2021 | Dec 31, 2021 | $7.24B | -2.4% |
| Q3 FY2021 | Sep 30, 2021 | $7.42B | +12.8% |
| Q2 FY2021 | Jun 30, 2021 | $6.22B | +20.9% |
| Q1 FY2021 | Mar 31, 2021 | $6.42B | +15.8% |
| Q4 FY2020 | Dec 31, 2020 | $7.42B | +26.2% |
| Q3 FY2020 | Sep 30, 2020 | $6.58B | +17.4% |
| Q2 FY2020 | Jun 30, 2020 | $5.14B | -9.5% |
| Q1 FY2020 | Mar 31, 2020 | $5.55B | +5.1% |
| Q4 FY2019 | Dec 31, 2019 | $5.88B | +1.4% |
| Q3 FY2019 | Sep 30, 2019 | $5.60B | +0.1% |
| Q2 FY2019 | Jun 30, 2019 | $5.69B | +0.7% |
| Q1 FY2019 | Mar 31, 2019 | $5.28B | +3.8% |
| Q4 FY2018 | Dec 31, 2018 | $5.80B | -2.6% |
| Q3 FY2018 | Sep 30, 2018 | $5.60B | -14.1% |
| Q2 FY2018 | Jun 30, 2018 | $5.65B | -20.9% |
| Q1 FY2018 | Mar 31, 2018 | $5.09B | -21.8% |
| Q4 FY2017 | Dec 31, 2017 | $5.95B | -18.7% |
| Q3 FY2017 | Sep 30, 2017 | $6.51B | – |
| Q2 FY2017 | Jun 30, 2017 | $7.14B | – |
| Q1 FY2017 | Mar 31, 2017 | $6.51B | – |
| Q4 FY2016 | Dec 31, 2016 | $7.32B | – |
See a number that looks wrong?